|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 根据皮肤光型和皮肤疾病进行光防护:来自专家小组的实用性建议显示文摘一、引言研究表明,在使用防晒霜时,应足量涂抹以达到2 mg/cm^(2)的推荐用量,这可以通过“茶匙法则(teaspoon rule)”或使用后1h内再次补涂的方法来实现。防晒霜的配方和质地需要根据个体的皮肤光型和皮肤疾病作出调整,然而大多数消费者仅依据SPF数值来选择防晒霜。 | Passeron T Lim HW Goh CL | 2021 | 中华皮肤科杂志2021，54，7： | 2 |
| 2 | 防晒剂的光防护作用和维生素D状态显示文摘众所周知,紫外线照射是人体维生素D状态的主要决定性因素。紫外线中有较小比例的UVB负责维生素D的合成,其合成和总体状态受多种内源性和外源性因素影响,包括基因多态性、年龄、地理位置、日照习惯、UVB剂量、着装、体表面积(BSA)暴露。维生素D3也可以从食物中获取,但从饮食中摄取的量很低。 | Passeron T Bouillon R Callender V 陈旭 孔佩慧 | 2020 | 中华皮肤科杂志2020，53，1： | 2 |
| 3 | Treatment of vitiligo by 308-nm excimer laser:an evaluation of variables affecting treatment response显示文摘 | Ostovari N Passeron T Zakaria W | 2004 | Lasers Surg Med2004，35，2： | 1 |
| 4 | SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmenta- tion显示文摘 | Passeron T Valencia JC Bertolotto C | 2007 | Proc Natl Acad Sei2007，104，13： | 1 |
| 5 | Treatment of vitiligo by topical calcipotriol显示文摘 | Chiavérini C Passeron T Ortonne JP | 2002 | J Eur Acad Dermatol Venereol2002，16，2： | 1 |
| 6 | Efficacy of intra- venous immunoglobulin in the treatment of scleromyxoedema 显示文摘 | Sillard L Passeron T Cardot-Leccia N | 2010 | Ann Dermatol Venereol2010，137，1： | 1 |
| 7 | Cyclic AMP promotes a peripheral distribution of melanosomes and stimulates melanophilin/Slac2-a and actin association显示文摘 | Passeron T Bahadoran P Bertolotto C | 2004 | The FASEB Journa2004，18，9： | 1 |
| 8 | Treatment of vitiligo by topical calcipotriol显示文摘 | Chiaverini C Passeron T Ortonne JP | 2002 | J Eur Acad Dermatol Venereol2002，16，2： | 1 |
| 9 | Topical tacrolimus and the 308-nm excimer Iaseria synergistic combination for the treatment of vitiligo 显示文摘 | Passeron T Ostovari N Zakaria W | 2004 | Arch Dermatol2004，140，9： | 1 |
| 10 | SOX9 is a key player in ultraviolet B--induced melanocyte differentiation and pigmentation显示文摘 | Passeron T ValenciaJC Bertolotto C | 2007 | Proc Natl Acad Sci U S A2007，104，35： | 1 |
| 11 | Paraneoplastic pemphigus presenting as erosive lichen planus显示文摘 | Passeron T Bahadoran P Lacour JP | 1999 | Br J Dermatol1999，140，3： | 1 |
| 12 | Topical tacrolimus and the 308-nm excimer laser:a synergistic combination for the treatment of vitiligo显示文摘 | Passeron T Ostovari N Zakaria W | 2004 | Arch Dermatol2004，140，9： | 1 |
| 13 | Signalling and chemo- sensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy 显示文摘 | Passeron T Lacour P Allegra M | 2011 | Exp Dermatol2011，20，12： | 1 |
| 14 | Topical tacrolimus and the 308-nm excimer laser:a synergistic combination for the treatment of vitiligo显示文摘 | Passeron T Ostovari N Zakaria W | 2004 | Arch Dermatol2004，140，9： | 1 |
| 15 | Glycoprotein nonmetastatic melanoma protein b,a melanocytic cell marker,is a melanosome-specffic and proteolytically released protein显示文摘 | Hoashi T Sato S Yamaguchi Y Passeron T Tamaki K Hearing VJ | | 0，，5： | 1 |
| 16 | Treatment of vitiligo by 308-nm excimer laser:an evaluation of variables affecting treatment response显示文摘 | Passeron T Zakaria W | 2004 | Lasers Surg Med2004，35，2： | 1 |
| 17 | Topical ta- crolimus and the 308 nm excimer laser: a synergistic com- bination for the treatment of vitiligo 显示文摘 | Passeron T Ostovari N Zakaria W | 2004 | Arch Dermatol2004，140，： | 1 |
| 18 | Physiopathology and genetics of vitiligo显示文摘 | Passeron T DrtonneJP | 2005 | J Autoimmu2005，25，： | 1 |
| 19 | Topical tacrolimus and the308-nm excimer laser:a synergistic combination for the treatment of vitiligo显示文摘 | Passeron T Ostovari N Zakaria W | 2004 | Arch Dermatol2004，140，9： | 1 |
| 20 | Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure显示文摘 | Ostovari N Passeron T Lacour JP | 2006 | Arch Dermatol2006，142，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员